MONICA ELENALOGHINMONICA ELENA LOGHIN9132LOGHIN, MONICA ELENAAssociate Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson25239666Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR, MD Anderson Community Clinical Oncology Program, Brain Tumor Trials CollaborativeNeuro-oncologyRandomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol. 2015 Feb; 17(2):266-73.Neuro Oncol2014-09-19T00:00:002014Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.1400 Holcombe BlvdHouston77030-4008TXAuthorship 1836999Authorship 194382224595679Le EM, Loghin MECurrent oncology reportsPosterior reversible encephalopathy syndrome: a neurologic phenomenon in cancer patients. Curr Oncol Rep. 2014 May; 16(5):383.Curr Oncol Rep2014-05-01T00:00:002014Posterior reversible encephalopathy syndrome: a neurologic phenomenon in cancer patients.LeukemiaNeuro-OncologyPalliative Care & Rehabilitation MedicineRadiation OncologyMD AndersonSUSAN LYNNEMCGOVERNSUSAN LYNNE MCGOVERN9341MCGOVERN, SUSAN LYNNEAssistant ProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorEDUARDOBRUERAEDUARDO BRUERA8804BRUERA, EDUARDOProfessorAMY BHEIMBERGERAMY B HEIMBERGER9035HEIMBERGER, AMY BProfessorROZANURIEVAROZA NURIEVA9236NURIEVA, ROZAAssistant ProfessorJOHN FREDERICKDE GROOTJOHN FREDERICK DE GROOT9019DE GROOT, JOHN FREDERICKProfessor1.001770.0074079891research areas0.7097690.025408266coauthor of13.81062.4627760similar to1125selected publicationsMARTAPENAS-PRADOMARTA PENAS-PRADO9235PENAS-PRADO, MARTAAssistant ProfessorAuthorship 2232451Authorship 2309541216343358Loghin M, Levin VACurrent treatment options in neurologyHeadache related to brain tumors. Curr Treat Options Neurol. 2006 Jan; 8(1):21-32.Curr Treat Options Neurol2006-01-01T00:00:002006Headache related to brain tumors.22086614Giglio P, Dhamne M, Hess KR, Gilbert MR, Groves MD, Levin VA, Kang SL, Ictech SE, Liu V, Colman H, Conrad CA, Loghin M, de Groot J, Yung WK, Puduvalli VKCancerPhase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer. 2012 Jul 15; 118(14):3599-606.Cancer2011-11-15T00:00:002011Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma.Authorship 252057218366964Penas-Prado M, Loghin MECurrent oncology reportsSpinal cord compression in cancer patients: review of diagnosis and treatment. Curr Oncol Rep. 2008 Jan; 10(1):78-85.Curr Oncol Rep2008-01-01T00:00:002008Spinal cord compression in cancer patients: review of diagnosis and treatment.19523357Vaillant B, Loghin MCurrent treatment options in neurologyTreatment of spinal cord tumors. Curr Treat Options Neurol. 2009 Jul; 11(4):315-24.Curr Treat Options Neurol2009-07-01T00:00:002009Treatment of spinal cord tumors.Authorship 267138118056194Loghin ME, Prados MD, Wen P, Junck L, Lieberman F, Fine H, Fink KL, Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T, DeAngelis LM, Robins IH, Aldape KD, Yung WKClinical cancer research : an official journal of the American Association for Cancer ResearchPhase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. Clin Cancer Res. 2007 Dec 01; 13(23):7133-8.Clin Cancer Res2007-12-01T00:00:002007Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.Authorship 2784082Authorship 27981515Authorship 2895025Authorship 2904683Authorship 3027401224859329Theeler BJ, Ellezam B, Yust-Katz S, Slopis JM, Loghin ME, de Groot JFJournal of neurologyProlonged survival in adult neurofibromatosis type I patients with recurrent high-grade gliomas treated with bevacizumab. J Neurol. 2014 Aug; 261(8):1559-64.J Neurol2014-05-25T00:00:002014Prolonged survival in adult neurofibromatosis type I patients with recurrent high-grade gliomas treated with bevacizumab.25038877Abouharb S, Ensor J, Loghin ME, Katz R, Moulder SL, Esteva FJ, Smith B, Valero V, Hortobagyi GN, Melhem-Bertrandt ABreast cancer research and treatmentLeptomeningeal disease and breast cancer: the importance of tumor subtype. Breast Cancer Res Treat. 2014 Aug; 146(3):477-86.Breast Cancer Res Treat2014-07-20T00:00:002014Leptomeningeal disease and breast cancer: the importance of tumor subtype.25897156Rapp SR, Case LD, Peiffer A, Naughton MM, Chan MD, Stieber VW, Moore DF, Falchuk SC, Piephoff JV, Edenfield WJ, Giguere JK, Loghin ME, Shaw EGJournal of clinical oncology : official journal of the American Society of Clinical OncologyDonepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical Trial. J Clin Oncol. 2015 May 20; 33(15):1653-9.J Clin Oncol2015-04-20T00:00:002015Donepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical Trial.74Professor10Assistant Professor14Associate Professor6Adjunct ProfessorCARLOSKAMIYA MATSUOKACARLOS KAMIYA MATSUOKA11825KAMIYA MATSUOKA, CARLOSAssistant Professor20399573Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Grewal J, Prabhu S, Loghin M, Gilbert MR, Jackson EFInternational journal of radiation oncology, biology, physicsRandomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2011 Apr 01; 79(5):1487-95.Int J Radiat Oncol Biol Phys2011-04-01T00:00:002011Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system.Authorship 842881Authorship 854219Authorship 858483Authorship 860519Authorship 866998Journal of Neuro-OncologyPosterior reversible encephalopathy syndrome in cancer patients. Journal of Neuro-Oncology. 1-10.Posterior reversible encephalopathy syndrome in cancer patientsCurrent Treatment Options in NeurologyThe treatment of malignant gliomas. Current Treatment Options in Neurology. 7:293-303.The treatment of malignant gliomasJournal of Neuro-OncologyA randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. Journal of Neuro-Oncology. 1-8.A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastomaInternational Journal of Radiation Oncology Biology PhysicsErratum. International Journal of Radiation Oncology Biology Physics. 84.ErratumJournal of Neuro-OncologyA phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. Journal of Neuro-Oncology. A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patientsD001932Disorders88848480.292688Brain NeoplasmsD013117Disorders821510.874765Spinal Cord CompressionD005910Disorders38619630.434313GliomaD054038Disorders40490.932622Posterior Leukoencephalopathy SyndromeAuthorship 8984782Authorship 9089796Authorship 9103506Authorship 92245313Authorship 92411011Authorship 940202715967092Gilbert MR, Loghin MCurrent treatment options in neurologyThe Treatment of Malignant Gliomas. Curr Treat Options Neurol. 2005 Jul; 7(4):293-303.Curr Treat Options Neurol2005-07-01T00:00:002005The Treatment of Malignant Gliomas.26900076Kamiya-Matsuoka C, Paker AM, Chi L, Youssef A, Tummala S, Loghin MEJournal of neuro-oncologyPosterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study. J Neurooncol. 2016 05; 128(1):75-84.J Neurooncol2016-02-22T00:00:002016Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study.27406589Weathers SP, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WKA, de Groot JFJournal of neuro-oncologyA randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. J Neurooncol. 2016 09; 129(3):487-494.J Neurooncol2016-07-12T00:00:002016A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.28925994Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJNature reviews. Clinical oncologyChimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018 Jan; 15(1):47-62.Nat Rev Clin Oncol2017-09-19T00:00:002017Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.29770225Naughton MJ, Case LD, Peiffer A, Chan M, Stieber V, Moore D, Falchuk S, Piephoff J, Edenfield W, Giguere J, Loghin M, Shaw EG, Rapp SRNeuro-oncology practiceQuality of life of irradiated brain tumor survivors treated with donepezil or placebo: Results of the WFU CCOP research base protocol 91105. Neurooncol Pract. 2018 May; 5(2):114-121.Neurooncol Pract2017-07-06T00:00:002017Quality of life of irradiated brain tumor survivors treated with donepezil or placebo: Results of the WFU CCOP research base protocol 91105.30359477Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA, Tremont-Lukats IW, Loghin ME, O'Brien BJ, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, de Groot JF, Alfred Yung WK, Penas-Prado MCancerPhase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. Cancer. 2019 02 01; 125(3):424-433.Cancer2018-10-25T00:00:002018Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.D005909Disorders40318030.447918GlioblastomaImmunologyNeurosurgeryDepartment of NeurosurgeryNeurosurgeryBaylor College of MedicineFREDERICKLANGFREDERICK LANG29.70706480000000-95.397162400000001037LANG, FREDERICKAdjunct Professor31755915de Groot J, Penas-Prado M, Alfaro-Munoz K, Hunter K, Pei BL, O'Brien B, Weathers SP, Loghin M, Kamiya Matsouka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, McCutcheon IE, Lang FF, Ferguson SD, Sawaya R, Colen R, Yadav SS, Blando J, Vence L, Allison J, Sharma P, Heimberger ABNeuro-oncologyWindow-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549.Neuro Oncol2020-04-15T00:00:002020Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.true1Adjunct ProfessorAdjunct ProfessorAuthorship 9872168Authorship 10437982335413951Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva RNature communicationsDistinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun. 2022 04 12; 13(1):1970.Nat Commun2022-04-12T00:00:002022Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.Authorship 1059579936128585Upadhyay R, Khose S, Pokhylevych H, Paulino AC, McAleer MF, Ghia A, Li J, Yeboa DN, Loghin M, Harrison R, O'Brien B, Kamiya-Matsuoka C, De Groot J, Puduvalli VK, Tatsui C, Alvarez-Breckenridge C, Prabhu S, Rhines L, Zaky W, Lin F, Weinberg JS, Fuller G, Sandberg DI, Johnson JM, McGovern SLNeuro-oncology advancesPatterns of failure after radiation therapy in primary spinal high-grade gliomas: A single institutional analysis. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac129.Neurooncol Adv2022-08-20T00:00:002022Patterns of failure after radiation therapy in primary spinal high-grade gliomas: A single institutional analysis.true1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1Assistant ProfessorAssistant Professortrue1Associate ProfessorAssociate Professortrue1Assistant ProfessorAssistant Professor